BioSpace News Archive

Sensei Biotherapeutics, Inc. today announced that Company management will present at Oppenheimer’s 33rd Annual Healthcare Conference.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California.

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured clinical batches of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb trial for Tourette Syndrome (“TS”).

Inari Medical, Inc. announced positive results from the FLAME study in high-risk/massive pulmonary embolism.

Medexus Pharmaceuticals is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023.

Amarin Corporation plc highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of Cardiology in New Orleans, LA, March 4-6, 2023.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced additional preliminary findings from its Parkinson’s Disease Phase 2 trial.

Nexcella, Inc. today announced that Ilya Rachman, M.D., Ph.D., Nexcella Executive Chairman, and Gabriel Morris, Nexcella President, will discuss recent positive NXC-201 clinical data in AL Amyloidosis and Multiple Myeloma in a fireside chat at the 35th Annual Roth Conference on Tuesday, March 14, 2023 at 10:30 a.m. PT.